L-Carnitine supplementation in childhood epilepsy: Current perspectives

Darryl C. De Vivo, Timothy P. Bohan, David L. Coulter, Fritz E. Dreifuss, Robert S. Greenwood, Douglas R. Nordli, W. Donald Shields, Carl Stafstrom, Ingrid Tein

Research output: Contribution to journalArticle

Abstract

In November 1996, a panel of pediatric neurologists met to update the consensus statement issued in 1989 by a panel of neurologists and metabolic experts on L-carnitine supplementation in childhood epilepsy. The panelists agreed that intravenous L-carnitine supplementation is clearly indicated for valproate (VPA)-induced hepatotoxicity, overdose, and other acute metabolic crises associated with carnitine deficiency. Oral supplementation is clearly indicated for the primary plasmalemmal carnitine transporter defect. The panelists concurred that oral L-carnitine supplementation is strongly suggested for the following groups as well: patients with certain secondary carnitine-deficiency syndromes, symptomatic VPA-associated hyperammonemia, multiple risk factors for VPA hepatotoxicity, or renal-associated syndromes; infants and young children taking VPA; patients with epilepsy using the ketogenic diet who have hypocarnitinemia; patients receiving dialysis; and premature infants who are receiving total parenteral nutrition. The panel recommended an oral L-carnitine dosage of 100 mg/kg/day, up to a maximum of 2 g/day. Intravenous supplementation for medical emergency situations usually exceeds this recommended dosage.

Original languageEnglish (US)
Pages (from-to)1216-1225
Number of pages10
JournalEpilepsia
Volume39
Issue number11
StatePublished - 1998
Externally publishedYes

Fingerprint

Carnitine
Epilepsy
Valproic Acid
Ketogenic Diet
Hyperammonemia
Total Parenteral Nutrition
Premature Infants
Dialysis
Emergencies
Pediatrics
Kidney

Keywords

  • Epilepsy
  • Ketogenic diet
  • L-Carnitine
  • Metabolism
  • Pediatric

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

De Vivo, D. C., Bohan, T. P., Coulter, D. L., Dreifuss, F. E., Greenwood, R. S., Nordli, D. R., ... Tein, I. (1998). L-Carnitine supplementation in childhood epilepsy: Current perspectives. Epilepsia, 39(11), 1216-1225.

L-Carnitine supplementation in childhood epilepsy : Current perspectives. / De Vivo, Darryl C.; Bohan, Timothy P.; Coulter, David L.; Dreifuss, Fritz E.; Greenwood, Robert S.; Nordli, Douglas R.; Shields, W. Donald; Stafstrom, Carl; Tein, Ingrid.

In: Epilepsia, Vol. 39, No. 11, 1998, p. 1216-1225.

Research output: Contribution to journalArticle

De Vivo, DC, Bohan, TP, Coulter, DL, Dreifuss, FE, Greenwood, RS, Nordli, DR, Shields, WD, Stafstrom, C & Tein, I 1998, 'L-Carnitine supplementation in childhood epilepsy: Current perspectives', Epilepsia, vol. 39, no. 11, pp. 1216-1225.
De Vivo DC, Bohan TP, Coulter DL, Dreifuss FE, Greenwood RS, Nordli DR et al. L-Carnitine supplementation in childhood epilepsy: Current perspectives. Epilepsia. 1998;39(11):1216-1225.
De Vivo, Darryl C. ; Bohan, Timothy P. ; Coulter, David L. ; Dreifuss, Fritz E. ; Greenwood, Robert S. ; Nordli, Douglas R. ; Shields, W. Donald ; Stafstrom, Carl ; Tein, Ingrid. / L-Carnitine supplementation in childhood epilepsy : Current perspectives. In: Epilepsia. 1998 ; Vol. 39, No. 11. pp. 1216-1225.
@article{d74bc2c12e434ce89b33b87374fdc141,
title = "L-Carnitine supplementation in childhood epilepsy: Current perspectives",
abstract = "In November 1996, a panel of pediatric neurologists met to update the consensus statement issued in 1989 by a panel of neurologists and metabolic experts on L-carnitine supplementation in childhood epilepsy. The panelists agreed that intravenous L-carnitine supplementation is clearly indicated for valproate (VPA)-induced hepatotoxicity, overdose, and other acute metabolic crises associated with carnitine deficiency. Oral supplementation is clearly indicated for the primary plasmalemmal carnitine transporter defect. The panelists concurred that oral L-carnitine supplementation is strongly suggested for the following groups as well: patients with certain secondary carnitine-deficiency syndromes, symptomatic VPA-associated hyperammonemia, multiple risk factors for VPA hepatotoxicity, or renal-associated syndromes; infants and young children taking VPA; patients with epilepsy using the ketogenic diet who have hypocarnitinemia; patients receiving dialysis; and premature infants who are receiving total parenteral nutrition. The panel recommended an oral L-carnitine dosage of 100 mg/kg/day, up to a maximum of 2 g/day. Intravenous supplementation for medical emergency situations usually exceeds this recommended dosage.",
keywords = "Epilepsy, Ketogenic diet, L-Carnitine, Metabolism, Pediatric",
author = "{De Vivo}, {Darryl C.} and Bohan, {Timothy P.} and Coulter, {David L.} and Dreifuss, {Fritz E.} and Greenwood, {Robert S.} and Nordli, {Douglas R.} and Shields, {W. Donald} and Carl Stafstrom and Ingrid Tein",
year = "1998",
language = "English (US)",
volume = "39",
pages = "1216--1225",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - L-Carnitine supplementation in childhood epilepsy

T2 - Current perspectives

AU - De Vivo, Darryl C.

AU - Bohan, Timothy P.

AU - Coulter, David L.

AU - Dreifuss, Fritz E.

AU - Greenwood, Robert S.

AU - Nordli, Douglas R.

AU - Shields, W. Donald

AU - Stafstrom, Carl

AU - Tein, Ingrid

PY - 1998

Y1 - 1998

N2 - In November 1996, a panel of pediatric neurologists met to update the consensus statement issued in 1989 by a panel of neurologists and metabolic experts on L-carnitine supplementation in childhood epilepsy. The panelists agreed that intravenous L-carnitine supplementation is clearly indicated for valproate (VPA)-induced hepatotoxicity, overdose, and other acute metabolic crises associated with carnitine deficiency. Oral supplementation is clearly indicated for the primary plasmalemmal carnitine transporter defect. The panelists concurred that oral L-carnitine supplementation is strongly suggested for the following groups as well: patients with certain secondary carnitine-deficiency syndromes, symptomatic VPA-associated hyperammonemia, multiple risk factors for VPA hepatotoxicity, or renal-associated syndromes; infants and young children taking VPA; patients with epilepsy using the ketogenic diet who have hypocarnitinemia; patients receiving dialysis; and premature infants who are receiving total parenteral nutrition. The panel recommended an oral L-carnitine dosage of 100 mg/kg/day, up to a maximum of 2 g/day. Intravenous supplementation for medical emergency situations usually exceeds this recommended dosage.

AB - In November 1996, a panel of pediatric neurologists met to update the consensus statement issued in 1989 by a panel of neurologists and metabolic experts on L-carnitine supplementation in childhood epilepsy. The panelists agreed that intravenous L-carnitine supplementation is clearly indicated for valproate (VPA)-induced hepatotoxicity, overdose, and other acute metabolic crises associated with carnitine deficiency. Oral supplementation is clearly indicated for the primary plasmalemmal carnitine transporter defect. The panelists concurred that oral L-carnitine supplementation is strongly suggested for the following groups as well: patients with certain secondary carnitine-deficiency syndromes, symptomatic VPA-associated hyperammonemia, multiple risk factors for VPA hepatotoxicity, or renal-associated syndromes; infants and young children taking VPA; patients with epilepsy using the ketogenic diet who have hypocarnitinemia; patients receiving dialysis; and premature infants who are receiving total parenteral nutrition. The panel recommended an oral L-carnitine dosage of 100 mg/kg/day, up to a maximum of 2 g/day. Intravenous supplementation for medical emergency situations usually exceeds this recommended dosage.

KW - Epilepsy

KW - Ketogenic diet

KW - L-Carnitine

KW - Metabolism

KW - Pediatric

UR - http://www.scopus.com/inward/record.url?scp=0031770664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031770664&partnerID=8YFLogxK

M3 - Article

C2 - 9821988

AN - SCOPUS:0031770664

VL - 39

SP - 1216

EP - 1225

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - 11

ER -